The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis

Background: A total of 2%–7% of non-small cell lung cancer (NSCLC) patients have anaplastic lymphoma kinase (ALK) mutations. At present, three or more generations of ALK inhibitors have been used for ALK-positive NSCLC treatment, including crizotinib, alectinib, ceritinib, and brigatinib. Although m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Helei, Sun, Dantong, Liu, Kewei, Jiang, Man, Liu, Dong, Zhu, Jingjuan, Zhou, Na, Cong, Jing, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511621/
https://www.ncbi.nlm.nih.gov/pubmed/31190983
http://dx.doi.org/10.2147/CMAR.S190098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511621/
https://www.ncbi.nlm.nih.gov/pubmed/31190983
http://dx.doi.org/10.2147/CMAR.S190098

Ejemplares similares